Literature DB >> 17401158

Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation.

Nadia Sahir1, Douglas E Brenneman, Joanna M Hill.   

Abstract

The Ts65Dn segmental mouse model of Down syndrome (DS) possesses a triplication of the section of chromosome 16 that is most homologous to the human chromosome 21 that is trisomic in DS. This model exhibits many of the characteristics of DS including small size, developmental delays, and a decline of cholinergic systems and cognitive function with age. Recent studies have shown that vasoactive intestinal peptide (VIP) systems are upregulated in aged Ts65Dn mice and that VIP dysregulation during embryogenesis is followed by the hypotonia and developmental delays as seen in both DS and in Ts65Dn mice. Additionally, astrocytes from aged Ts65Dn brains do not respond to VIP stimulation to release survival-promoting substances. To determine if VIP dysregulation is age-related in Ts65Dn mice, the current study examined VIP and VIP receptors (VPAC-1 and VPAC-2) in postnatal day 8 Ts65Dn mice. VIP and VPAC-1 expression was significantly increased in the brains of trisomic mice compared with wild-type mice. VIP-binding sites were also significantly increased in several brain areas of young Ts65Dn mice, especially in the cortex, caudate/putamen, and hippocampus. Further, in vitro treatment of normal neurons with conditioned medium from VIP-stimulated Ts65Dn astrocytes from neonatal mice did not enhance neuronal survival. This study indicates that VIP anomalies are present in neonatal Ts65Dn mice, a defect occurs in the signal transduction mechanism of the VPAC-1 VIP receptor, cortical astrocytes from neonatal brains are dysfunctional, and further, that VIP dysregulation may play a significant role in DS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17401158     DOI: 10.1385/JMN:30:3:329

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  77 in total

1.  Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation.

Authors:  K B Nelson; J K Grether; L A Croen; J M Dambrosia; B F Dickens; L L Jelliffe; R L Hansen; T M Phillips
Journal:  Ann Neurol       Date:  2001-05       Impact factor: 10.422

2.  Altered astrocyte calcium homeostasis and proliferation in theTs65Dn mouse, a model of Down syndrome.

Authors:  Linda L Bambrick; Paul J Yarowsky; Bruce K Krueger
Journal:  J Neurosci Res       Date:  2003-07-01       Impact factor: 4.164

3.  Regional distribution of guanine nucleotide-sensitive and guanine nucleotide-insensitive vasoactive intestinal peptide receptors in rat brain.

Authors:  J M Hill; A Harris; D I Hilton-Clarke
Journal:  Neuroscience       Date:  1992-06       Impact factor: 3.590

4.  Vasoactive intestinal peptide gene expression from embryos to aging rats.

Authors:  I Gozes; P Schächter; Y Shani; E Giladi
Journal:  Neuroendocrinology       Date:  1988-01       Impact factor: 4.914

5.  Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat.

Authors:  J M Hill; I Gozes; J L Hill; M Fridkin; D E Brenneman
Journal:  Peptides       Date:  1991 Jan-Feb       Impact factor: 3.750

Review 6.  Preliminary characterization of the central nervous system in partial trisomy 16 mice.

Authors:  D M Holtzman; J Kilbridge; K S Chen; J Rabin; R Luche; E Carlson; C J Epstein; W C Mobley
Journal:  Prog Clin Biol Res       Date:  1995

7.  Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.

Authors:  T B Usdin; T I Bonner; E Mezey
Journal:  Endocrinology       Date:  1994-12       Impact factor: 4.736

8.  Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome.

Authors:  D M Holtzman; D Santucci; J Kilbridge; J Chua-Couzens; D J Fontana; S E Daniels; R M Johnson; K Chen; Y Sun; E Carlson; E Alleva; C J Epstein; W C Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

9.  Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP.

Authors:  Margalit Zusev; Illana Gozes
Journal:  Regul Pept       Date:  2004-12-15

10.  Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide.

Authors:  D E Brenneman; E A Neale; G A Foster; S W d'Autremont; G L Westbrook
Journal:  J Cell Biol       Date:  1987-06       Impact factor: 10.539

View more
  7 in total

1.  Altered distribution of hippocampal interneurons in the murine Down Syndrome model Ts65Dn.

Authors:  Samuel Hernández-González; Raúl Ballestín; Rosa López-Hidalgo; Javier Gilabert-Juan; José Miguel Blasco-Ibáñez; Carlos Crespo; Juan Nácher; Emilio Varea
Journal:  Neurochem Res       Date:  2014-11-16       Impact factor: 3.996

2.  Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome.

Authors:  Aarti Ruparelia; Matthew L Pearn; William C Mobley
Journal:  Curr Opin Neurobiol       Date:  2012-05-30       Impact factor: 6.627

3.  Regardless of genotype, offspring of VIP-deficient female mice exhibit developmental delays and deficits in social behavior.

Authors:  Maria A Lim; Conor M Stack; Katrina Cuasay; Madeleine M Stone; Hewlet G McFarlane; James A Waschek; Joanna M Hill
Journal:  Int J Dev Neurosci       Date:  2008-03-14       Impact factor: 2.457

4.  Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry.

Authors:  Joanna M Hill; Janet M Hauser; Lia M Sheppard; Daniel Abebe; Irit Spivak-Pohis; Michal Kushnir; Iris Deitch; Illana Gozes
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

Review 5.  Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics.

Authors:  Nicole Créau
Journal:  Neural Plast       Date:  2012-07-12       Impact factor: 3.599

6.  Prenatal treatment prevents learning deficit in Down syndrome model.

Authors:  Maddalena Incerti; Kari Horowitz; Robin Roberson; Daniel Abebe; Laura Toso; Madeline Caballero; Catherine Y Spong
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

7.  Prevention of developmental delays in a Down syndrome mouse model.

Authors:  Laura Toso; Irene Cameroni; Robin Roberson; Daniel Abebe; Stephanie Bissell; Catherine Y Spong
Journal:  Obstet Gynecol       Date:  2008-12       Impact factor: 7.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.